Expression of triggering receptor on myeloid cell 1 and histocompatibility complex molecules in sepsis and major abdominal surgery

Table 1 Patients’ data

Group	Sex	Age	Diagnosis	Procedure	Survival	HLA-DR (%)		TREM-1 (MFI)
						pre-s post-s		pre-s post-s
Surgery	M	52	Diverticulitis	Hemicolectomy	L	N	82	56.8	46.5
Surgery	F	43	Portal hypertension	Gastro-gastro2	L	64.18	87.56	50.8	82.9
Surgery	F	76	GRD	ARS4	D	49.8	82.19	73.4	102.6
Surgery	F	50	GRD	Nissen funduplication	L	77.9	63.45	39.1	44.1
Surgery	M	52	GRD	Nissen funduplication	L	83.82		94
Surgery	F	39	Choledocal cyst	H–J3	L	59.8	53.07	32.8	62.4
Surgery	M	62	Cholangiocarcinoma	H–J	L	82.38		63.7
Septic	M	48	AP	NA	D	52.88		36.9
Septic	M	53	Acute abdominal pain	Splenectomy	D	22		59.9
Septic	M	73	Gastric cancer	Total Gastrectomy	D	44.3		48.3
Septic	M	58	AP	Laparotomy	L	33.98		29.1
Septic	F	33	Pancreatic neoplasm1	Laparotomy	L	67.28		50.06
Septic	F	83	Obstructive jaundice	Cholecystectomy	D	70.97		54.7
Septic	M	50	AP	Pseudocyst drainage	D	68.82		90.7
Septic	F	58	Bile duct injury	H–J3	L	37.63		27.8
Septic	M	24	Pancreatic fistulae	NA	L	75.4		54.8
Septic	M	50	EC5	NA	D	18.6		53.6
Septic	M	46	AP	Laparotomy	D	38.12		63.1
Healthy	M	67	NA	None	L	81.37		47.6
Healthy	M	42	NA	None	L	53.37		35.2
Healthy	M	55	NA	None	L	87.5		83
Healthy	M	24	NA	None	L	82.4		37.8
Healthy	M	50	NA	None	L	70.31		44.3
Healthy	M	29	NA	None	L	89.66		67.3
Healthy	F	24	NA	None	L	50.92		21.4
Healthy	M	20	NA	None	L	84.43		35.9
Healthy	F	23	NA	None	L	35.87		24.1
Healthy	M	20	NA	None	L	63.16		21.4

A = years; M = masculine; F = feminine; AP = acute pancreatitis; GRD = gastroesophageal reflux disease; L=live; D=death;

¹mixed papillary neoplasm of the pancreas;

²gastro-gastro-anastomosis;

³H–J = hepatico-jejunostomy;

⁴ARS = anti-reflux surgery;

⁵EC = emphysematous cholecystitis; NA = not applicable; pre-s = pre-operative; post-s = post-operative.